Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
Recruiting · NCT07110103 · Registry updated 2026-02-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC | SCLC; SCLC, Extensive Stage | Recruiting | Phase 2 | 2026-02-27 | NCT07110103 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 294 |
| Dizal (Jiangsu) Pharmaceutical Co., Ltd. | 4 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Hospital, Chinese Academy of Medical Sciences | Beijing | China | 20 |
| Xinqiao Hospital, Third Military Medical University | Chongqing | China | 1 |